Literature DB >> 30310730

The Transactivating Function 2 (AF-2) of Estrogen Receptor (ER) α is Indispensable for ERα-mediated Physiological Responses and AF-1 Activity.

Yukitomo Arao1, Katherine J Hamilton1, Kenneth S Korach1.   

Abstract

Estrogen has various physiological functions and the estrogen receptor (ER) is a key regulator of those functions. ERα is a ligand-dependent transcription factor and that activity is mediated by the transactivating function-1 (AF-1) in the N-terminal domain and transactivating function-2 (AF-2) in the C-terminal ligand-binding domain. The functions of ERα AF-1 and AF-2 have been characterized by various in vitro experiments, however, there is still less information about the in vivo physiological functions of ERα AF-1 and AF-2. Recently, we established a genetically mutated ERα AF-2 knock-in mouse (AF2ERKI) that possesses L543A, L544A mutated-ERα. This AF-2 core mutation disrupted AF-2 function and resulted in ERα null phenotypes. This mouse model revealed that proper AF-2 core structure and function are indispensable for ERα-mediated physiological responses and AF-1 functionality. AF2ER mutation reverses the ERα antagonists to agonists and that activity is mediated by AF-1 solely. The pure antagonist, ICI182780/fulvestrant, activated several estrogen-mediated physiological responses in the AF2ERKI mouse. The AF2ERKI mouse model will be able to discern estrogen physiological functions which involve AF-1.

Entities:  

Keywords:  Antagonist reversal; Knock-in mouse; SERMs

Year:  2013        PMID: 30310730      PMCID: PMC6177219          DOI: 10.4236/ojemd.2013.34A2002

Source DB:  PubMed          Journal:  Open J Endocr Metab Dis        ISSN: 2165-7424


  48 in total

Review 1.  Sex steroids and bone.

Authors:  J E Compston
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  Identification of phosphorylation sites in the mouse oestrogen receptor.

Authors:  H Lahooti; R White; S A Hoare; D Rahman; D J Pappin; M G Parker
Journal:  J Steroid Biochem Mol Biol       Date:  1995-12       Impact factor: 4.292

Review 3.  Tamoxifen: a most unlikely pioneering medicine.

Authors:  V Craig Jordan
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

4.  pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167.

Authors:  P B Joel; J Smith; T W Sturgill; T L Fisher; J Blenis; D A Lannigan
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

5.  Ligand-based identification of environmental estrogens.

Authors:  C L Waller; T I Oprea; K Chae; H K Park; K S Korach; S C Laws; T E Wiese; W R Kelce; L E Gray
Journal:  Chem Res Toxicol       Date:  1996-12       Impact factor: 3.739

6.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

7.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

8.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

9.  Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance.

Authors:  Lin Zhu; William C Brown; Qing Cai; Andrée Krust; Pierre Chambon; Owen P McGuinness; John M Stafford
Journal:  Diabetes       Date:  2012-09-10       Impact factor: 9.461

10.  Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity.

Authors:  Ross S Thomas; Naveed Sarwar; Fladia Phoenix; R Charles Coombes; Simak Ali
Journal:  J Mol Endocrinol       Date:  2008-04       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.